Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials

ConclusionsThe percentage of patients with pMDD/pGAD reduced from baseline over 1  year of treatment with tofacitinib or adalimumab. Effective treatment of underlying RA may lead to improvements in depression and anxiety, based on the SF-36 MCS. Specially designed studies using gold-standard diagnostic tools would be warranted to investigate this further.Video Abstract available for this article.Trial RegistrationNCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT02187055.Video Abstract (MP4 204475 KB)
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research